Skip to main content
SpringerLink
Log in

A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: β2-microglobulin associated with time to progression

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Bortezomib is approved for the treatment of patients with relapsed or refractory multiple myeloma (MM), but only a few clinical studies for Japanese patients who were treated with bortezomib have been reported. We retrospectively analyzed 40 patients with relapsed or refractory MM who have received bortezomib at three collaborating centers in Miyagi prefecture in Japan. All the patients have been received bortezomib in combination with dexamethasone. Responses were determined using International Myeloma Working Group uniform response criteria. The overall response was observed in 30 patients (75%), including very good partial response in 8 patients (20%), and partial response in 22 patients (55%). The median time to disease progression was 8.7 months, and the median overall survival has not been reached. The factors affecting time to disease progression were International Staging System stage, serum β2-microglobulin level, and number of treatment cycles. The most common grade 3 and 4 adverse events were thrombocytopenia (50%), peripheral neuropathy (25%), leukopenia (25%), and herpes zoster infection (25%). Thus, bortezomib is well tolerated and effective for Japanese patients with relapsed or refractory MM. Our results suggest that serum β2-microglobulin level may be a marker of prognosis on bortezomib therapy for patients with relapsed or refractory MM although further studies are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111:2962–72. doi:10.1182/blood-2007-10-078022.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–17. doi:10.1056/NEJMoa030288.

    Article  CAS  PubMed  Google Scholar 

  3. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165–72. doi:10.1111/j.1365-2141.2004.05188.x.

    Article  CAS  PubMed  Google Scholar 

  4. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–98. doi:10.1056/NEJMoa043445.

    Article  CAS  PubMed  Google Scholar 

  5. Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892–901. doi:10.1200/JCO.2006.10.5460.

    Article  CAS  PubMed  Google Scholar 

  6. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005;129:776–83. doi:10.1111/j.1365-2141.2005.05540.x.

    Article  CAS  PubMed  Google Scholar 

  7. Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006;91:1498–505.

    CAS  PubMed  Google Scholar 

  8. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–17. doi:10.1056/NEJMoa0801479.

    Article  CAS  PubMed  Google Scholar 

  9. Gotoh A, Ohyashiki K, Oshimi K, Usui N, Hotta T, Dan K, et al. Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the “lung injury by bortezomib” joint committee of the Japanese society of hematology and the Japanese society of clinical hematology. Int J Hematol. 2006;84:406–12. doi:10.1532/IJH97.06142.

    Article  CAS  PubMed  Google Scholar 

  10. Ozaki S, Tanaka O, Fujii S, Shigekiyo Y, Miki H, Choraku M, et al. Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma. Int J Hematol. 2007;86:180–5. doi:10.1532/IJH97.07030.

    Article  CAS  PubMed  Google Scholar 

  11. Ogawa Y, Tobinai K, Ogura M, Ando K, Tsuchiya T, Kobayashi Y, et al. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Cancer Sci. 2008;99:140–4.

    CAS  PubMed  Google Scholar 

  12. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–57. doi:10.1046/j.1365-2141.2003.04355.x.

    Article  Google Scholar 

  13. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–54. doi:10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U.

    Article  CAS  PubMed  Google Scholar 

  14. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20. doi:10.1200/JCO.2005.04.242.

    Article  PubMed  Google Scholar 

  15. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73. doi:10.1038/sj.leu.2404284.

    Article  CAS  PubMed  Google Scholar 

  16. Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006;91:929–34.

    CAS  PubMed  Google Scholar 

  17. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood. 2005;106:2977–81. doi:10.1182/blood-2005-02-0691.

    Article  CAS  PubMed  Google Scholar 

  18. Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007;21:151–7. doi:10.1038/sj.leu.2404442.

    Article  CAS  PubMed  Google Scholar 

  19. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol. 2007;137:429–35. doi:10.1111/j.1365-2141.2007.06585.x.

    Article  CAS  PubMed  Google Scholar 

  20. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24:3113–20. doi:10.1200/JCO.2005.04.7779.

    Article  CAS  PubMed  Google Scholar 

  21. Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144:895–903.

    Article  CAS  PubMed  Google Scholar 

  22. Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008;26:4784–90. doi:10.1200/JCO.2007.14.9641.

    Article  CAS  PubMed  Google Scholar 

  23. Terpos E, Sezer O, Croucher P, Dimopoulos MA. Myeloma bone disease and proteasome inhibition therapies. Blood. 2007;110:1098–104. doi:10.1182/blood-2007-03-067710.

    Article  CAS  PubMed  Google Scholar 

  24. Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol. 2005;131:71–3. doi:10.1111/j.1365-2141.2005.05733.x.

    Article  CAS  PubMed  Google Scholar 

  25. Zangari M, Yaccoby S, Cavallo F, Esseltine D, Tricot G. Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma. 2006;7:109–14. doi:10.3816/CLM.2006.n.047.

    Article  CAS  PubMed  Google Scholar 

  26. Heider U, Kaiser M, Muller C, Jakob C, Zavrski I, Schulz CO, et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol. 2006;77:233–8. doi:10.1111/j.1600-0609.2006.00692.x.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan

    Hiroto Ohguchi, Joji Yamamoto, Yasushi Onishi, Minami Fujiwara Yamada, Kenichi Ishizawa, Junichi Kameoka & Hideo Harigae

  2. Department of Internal Medicine, Osaki Citizen Hospital, 2-3-10 Senjuji-machi, Furukawa, Osaki, 989-6183, Japan

    Hiroto Ohguchi, Tomohiro Sugawara & Izumi Ishikawa

  3. Department of Hematology, Miyagi Cancer Center, 47-1 Nodayama, Medeshima-Shiode, Natori, 981-1293, Japan

    Mitsutaka Okuda & Yasuo Tomiya

Authors
  1. Hiroto Ohguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomohiro Sugawara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Izumi Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mitsutaka Okuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasuo Tomiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joji Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasushi Onishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Minami Fujiwara Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kenichi Ishizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Junichi Kameoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hideo Harigae
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideo Harigae.

About this article

Cite this article

Ohguchi, H., Sugawara, T., Ishikawa, I. et al. A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: β2-microglobulin associated with time to progression. Int J Hematol 89, 342–347 (2009). https://doi.org/10.1007/s12185-009-0279-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-009-0279-4

Keywords

Search

Navigation